Swedencare AB (publ) (SECARE.ST)
SEK 38.85
(0.65%)
SEK 38.85
(0.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 164.8 Million SEK | -83.77% |
| 2022 | 1.01 Billion SEK | 163.19% |
| 2021 | 385.87 Million SEK | 145.24% |
| 2020 | 157.34 Million SEK | 69.09% |
| 2019 | 93.05 Million SEK | 26.56% |
| 2018 | 73.52 Million SEK | 15.33% |
| 2017 | 63.74 Million SEK | 49.96% |
| 2016 | 42.51 Million SEK | 14.81% |
| 2015 | 37.02 Million SEK | 147.81% |
| 2014 | 14.94 Million SEK | 39.82% |
| 2013 | 10.68 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 59.4 Million SEK | -82.43% |
| 2024 Q1 | 338 Million SEK | 514.55% |
| 2024 Q3 | 369 Million SEK | 521.21% |
| 2023 Q1 | 285.8 Million SEK | -0.12% |
| 2023 FY | 164.8 Million SEK | -83.77% |
| 2023 Q2 | 305 Million SEK | 6.72% |
| 2023 Q3 | 333 Million SEK | 9.18% |
| 2023 Q4 | 55 Million SEK | -83.48% |
| 2022 Q1 | 187.04 Million SEK | 115.1% |
| 2022 FY | 1.01 Billion SEK | 163.19% |
| 2022 Q3 | 256.55 Million SEK | -3.04% |
| 2022 Q4 | 286.14 Million SEK | 11.53% |
| 2022 Q2 | 264.61 Million SEK | 41.47% |
| 2021 Q2 | 94.77 Million SEK | 19.46% |
| 2021 Q3 | 124.8 Million SEK | 31.68% |
| 2021 Q4 | 86.95 Million SEK | -30.32% |
| 2021 Q1 | 79.33 Million SEK | 25.72% |
| 2021 FY | 385.87 Million SEK | 145.24% |
| 2020 Q3 | 43.51 Million SEK | 83.43% |
| 2020 Q2 | 23.72 Million SEK | -12.14% |
| 2020 FY | 157.34 Million SEK | 69.09% |
| 2020 Q4 | 63.1 Million SEK | 45.02% |
| 2020 Q1 | 27 Million SEK | 10.2% |
| 2019 Q3 | 23.4 Million SEK | 7.1% |
| 2019 Q2 | 21.85 Million SEK | -6.14% |
| 2019 Q1 | 23.28 Million SEK | 12.67% |
| 2019 FY | 93.05 Million SEK | 26.56% |
| 2019 Q4 | 24.5 Million SEK | 4.68% |
| 2018 Q1 | 15.91 Million SEK | -6.11% |
| 2018 Q3 | 18.38 Million SEK | -0.86% |
| 2018 Q4 | 20.66 Million SEK | 12.39% |
| 2018 FY | 73.52 Million SEK | 15.33% |
| 2018 Q2 | 18.54 Million SEK | 16.52% |
| 2017 Q3 | 16.48 Million SEK | 21.24% |
| 2017 Q4 | 16.95 Million SEK | 2.86% |
| 2017 FY | 63.74 Million SEK | 49.96% |
| 2017 Q1 | 16.71 Million SEK | 55.0% |
| 2017 Q2 | 13.59 Million SEK | -18.68% |
| 2016 Q1 | 11.55 Million SEK | -47.88% |
| 2016 Q4 | 10.78 Million SEK | -5.28% |
| 2016 Q3 | 11.38 Million SEK | 32.84% |
| 2016 Q2 | 8.57 Million SEK | -25.8% |
| 2016 FY | 42.51 Million SEK | 14.81% |
| 2015 Q1 | 4.12 Million SEK | 0.0% |
| 2015 FY | 37.02 Million SEK | 147.81% |
| 2015 Q4 | 22.16 Million SEK | 325.23% |
| 2015 Q2 | 5.53 Million SEK | 34.14% |
| 2015 Q3 | 5.21 Million SEK | -5.77% |
| 2014 FY | 14.94 Million SEK | 39.82% |
| 2013 FY | 10.68 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -2400.0% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 34721.849% |
| BioGaia AB (publ) | 950.19 Million SEK | 82.656% |
| Enzymatica AB (publ) | 31.86 Million SEK | -417.214% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 4324.558% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 1831211.111% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 7951.358% |
| Nanexa AB (publ) | 59.15 Million SEK | -178.581% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -927.88% |
| ODI Pharma AB | -1.34 Million SEK | 12383.52% |
| Orexo AB (publ) | 549.9 Million SEK | 70.031% |
| Probi AB (publ) | 220.21 Million SEK | 25.163% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 98.827% |
| Toleranzia AB | -919 Thousand SEK | 18032.535% |
| Vivesto AB | -10.65 Million SEK | 1646.547% |